DNMT3A and PTPN11 mutation were associated with short OS in the favorable risk ELN group (i.e. de novo CN-AML with mutated NPM1 without FLT3-ITD or de novo CN-AML with doubly-mutated CEBPA, n=10) (Supplementary Figure S9). This evidence concerns the gene CEBPA and acute myeloid leukemia.